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MATERIALS AND METHODS 
Protein expression and purification  
Proteins were produced and purified using previously-described methods (34). Briefly, NIH45-46 
IgG was expressed by transient transfection in HEK293-6E cells. Secreted IgG was purified from 
cell supernatants using protein A affinity chromatography (GE Healthcare). Fab fragments were 
prepared by digesting purified IgG with immobilized papain (Pierce) at 10 mg/mL and then 
separating Fabs from Fc-containing proteins using protein A chromatography and Superdex 200 
16/60 size exclusion chromatography. For crystallization trials, the NIH45-46 Fab for crystallization 
experiments was concentrated to 11 mg/mL in 20 mM Tris pH 8.0, 150 mM sodium chloride, 0.02% 
sodium azide (TBS). Substitutions in heavy chain residue 54 of NIH45-46, 3BNC55, 12A12, 
3BNC117 and 3BNC60 were introduced using a Quikchange II kit (Agilent technologies). Wild 
type, mutant forms and chain swapped versions of these proteins were expressed as IgGs in 
HEK293-6E cells and purified by protein A chromatography as described for NIH45-46 IgG. 
Proteins were stored at a concentration of 1 mg/mL for neutralization assays in either 10 mM 
sodium citrate pH 3.05, 50 mM sodium chloride, 0.02% sodium azide or in TBS (12A12 and 
12A12Y54W) or in phosphate buffered saline (NIH45-46 mutated/truncated in CDRH3 and NIH45-
46/VRC01 heavy and light chain swapped antibodies (Abs)) prior to dilution into neutral pH cell 
media. For SPR analyses, NIH45-46 and NIH45-46G54W heavy chains were subcloned into the pTT5 
(NRC-BRI) expression vector to encode C-terminal 6x-His tagged Fab heavy chains (VH-CH1–6x-
His tag), and the heavy chain expression vectors were co-transfected with the appropriate light chain 
vector into HEK293-6E cells. Supernatants were collected after 7 days, buffer exchanged into TBS 
and loaded on a Ni2+-NTA affinity column (Qiagen). Fabs were eluted using TBS supplemented 
with 250 mM imidazole and further purified by Superdex 200 10/300 size exclusion 
chromatography (GE Healthcare) in TBS.  
Genes encoding truncated 93TH053, CAP244.2.00.D3, and Q259.d2.17 gp120 cores 
including the deletions and modifications described in ref. (25) were chemically synthesized 
(BlueHeron). An extra disulfide bond was introduced into 93TH053 by changing the Val65 and 
Ser115 codons into cysteines. The modified core genes were subcloned into the pACgp67b 
expression vector (BD Biosynthesis) to include a C-terminal 6x-His tag, expressed in baculovirus-
infected insect cells, and purified from insect cell supernatants as previously described (34). For 
crystallization experiments, purified NIH45-46 Fab and 93TH057 gp120 were incubated at a 1:1 
molar ratio and treated with 40 kU of Endoglycosidase H (New England Biolabs) for 16 hours at 37° 
C. The complex was purified after the incubation by Superdex 200 10/300 size exclusion 
chromatography (GE Healthcare) and then concentrated to OD280 = 9.6 in 20 mM Tris pH 8.0, 300 
mM sodium chloride, 0.02% sodium azide. 
 
Crystallization 
Crystallization screening was done by vapor diffusion in sitting drops by a Mosquito® 
crystallization robot (TTP labs) using 400 nL drops (1:1 protein to reservoir ratio) utilizing 
commercially available crystallization screens (Hampton). Initial crystallization hits for Fab NIH45-
46 and for NIH45-46–93TH057 complex were identified using the PEGRx HT™ (Hampton) screen 
and then manually optimized. Thin needle-like crystals of Fab NIH45-46 (space group P212121, a = 
49.4 Å, b = 87.4 Å, c = 166.4 Å; one molecule per asymmetric unit) were obtained upon mixing a 
protein solution at 11 mg/mL with 12% polyethylene glycol 20,000, 0.1 M sodium acetate pH 5.0, 
0.1 M sodium/potassium tartrate, 0.02 M ammonium sulfate at 20 °C. Crystals were briefly soaked 
in mother liquor solution supplemented with 15% and then 30% glycerol before flash cooling in 
liquid nitrogen. Crystals of the NIH45-46–93TH057 complex (space group P212121, a = 69.1 Å, b = 
70.5 Å, c = 217.7 Å; one molecule per asymmetric unit) were obtained upon mixing a protein 
solution at OD280=9.6 with 12% isopropanol, 10% polyethylene glycol 10,000, 0.1 M sodium citrate 
pH 5.0 at 20 °C. Complex crystals were cryo-cooled by covering the crystallization drops with 
paraffin oil to prevent evaporation and then adding an excess of 20% isopropanol, 5% glycerol, 10% 
polyethylene glycol, 0.1 M sodium citrate pH 5.0 to the drops prior to mounting and flash cooling 
the crystals in liquid nitrogen.  
 
Data collection, structure solution and refinement 
X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) 
beamline 12-2 using a Pilatus 6M pixel detector (Dectris). The data were indexed, integrated and 
scaled using XDS (35). The Fab NIH45-46 structure was solved by molecular replacement using 
Phaser (36) and the VHVL and CH1CL domains of the VRC01 Fab (PDB code 3NGB) as separate 
search models. The model was refined to 2.6 Å resolution using an iterative approach involving 
refinement using the Phenix crystallography package (37) and manually fitting models into electron 
density maps using Coot (38). The final model (Rwork = 18.4%; Rfree = 23.8%) includes 3380 protein 
atoms, 125 water molecules and 37 ligand atoms, including N-Acetylglucosamine, glycerol and a 
sulfate ion (Table S1). 96.5%, 3.3% and 0.2% of the residues were in the favored, allowed and 
disallowed regions, respectively, of the Ramachandran plot. The first glutamine of the NIH45-46 
heavy chain was modeled as 5-pyrrolidone-2-carboxylic acid. 
A search model for solving the NIH45-46–93TH057 complex was created by superimposing 
the refined structure of the NIH45-46 Fab on the VRC01 Fab in the structure of VRC01–93TH057 
(PDB code 3NGB). A molecular replacement solution was found as described above using separate 
search models for the VHVL domains of NIH45-46 complexed with 93TH057 and the CH1CL 
domains of NIH45-46. (Table S1). The complex structure was refined to 2.45 Å resolution as 
described for the Fab structure. To reduce model bias, the CDRH3 of NIH45-46 was omitted from 
the model and then built into electron density maps after a few rounds of refinement. Formation of 
an introduced disulfide bond between residues 65 and 115 in 93TH057 gp120 was verified in a Fo - 
Fc annealed omit electron density map contoured at 3.0 σ. The final model (Rwork = 20.7%; Rfree = 
25.6%) includes 5989 protein atoms, 67 water molecules and 148 atoms of carbohydrates, citrate 
and chloride ions (Table S1). 96.1%, 3.5% and 0.4% of the residues were in the favored, allowed 
and disallowed regions, respectively, of the Ramachandran plot. Disordered residues that were not 
included in the model were residues 1-2 of the NIH45-46 light chain, residues 133-136 and 219-221 
of the heavy chain, and residues 302-308 (V3 substitution), residues 397-408 (a total of 6 residues 
from V4) and the 6x-His tag of 93TH057. The first glutamine of the NIH45-46 heavy chain was 
modeled as 5-pyrrolidone-2-carboxylic acid. 
Buried surface areas were calculated using AreaIMol in CCP4 (39) and a 1.4 Å probe. 
Superimposition calculations were done and molecular representations were generated using PyMol 
(40). 	  
Surface Plasmon Resonance (SPR) measurements 
The binding of gp120 core proteins to wild-type NIH45-46 Fab and to mutant (NIH45-46G54W) Fab 
was compared using a Biacore T100 instrument (GE Healthcare). Purified NIH45-46 and NIH45-
46G54W Fabs were immobilized at coupling densities of 500 resonance units (RU) or 1500 RU on a 
CM5 sensor chip (Biacore) in 10 mM acetate pH 5.0 using primary amine coupling chemistry as 
described in the Biacore manual. One of the four flow cells on each sensor chip was mock-coupled 
using buffer to serve as a blank. Experiments were performed at 25˚C in 20 mM HEPES, pH 7.0, 
150 mM sodium chloride and 0.005% (v/v) surfactant P20, and the sensor chips were regenerated 
using 10 mM glycine, pH 2.5. gp120 core proteins were injected in a two-fold dilution series at 
concentrations ranging from 500 nM to 31.2 nM at a flow rate of 70 µL/min. After subtracting the 
signal from the mock-coupled flow cell, kinetic data were globally fit to a 1:1 binding model 
(Biacore evaluation software) to derive on- and off-rate constants, which were used to calculate 
affinities as KD = kd/ka.  
 
In vitro neutralization assays 
A previously-described pseudovirus neutralization assay was used to compare the neutralization 
potencies of wild-type and mutant IgGs (41). Neutralization assays were performed either by the 
Collaboration for AIDS Vaccine Discovery (CAVD) core neutralization facility (Fig 4A, Tables S5, 
S6) or by our laboratory (Fig. S5C, S8, Tables S2, S8) using the same protocol (41). Briefly, 
pseudoviruses were generated in HEK293T cells by co-transfection of an Env-expressing vector and 
a replication-incompetent backbone plasmid. Neutralization was assessed by measuring the 
reduction in luciferase reporter gene expression in the presence of a potential inhibitor following a 
single round of pseudovirus infection in TZM-bl cells. Antibodies were pre-incubated with 250 
infectious viral units in a three or four-fold dilution series for one hour at 37°C before adding 10,000 
TZM-bl cells per well for a two-day incubation. Cells were then lysed and luciferase expression was 
measured using BrightGlo (Promega) and a Victor3 luminometer (PerkinElmer). Nonlinear 
regression analysis using the program Prism (GraphPad) was used to calculate the concentrations at 
which half-maximal inhibition was observed (IC50 values) as described (42). Samples were initially 
screened in duplicates. Reagents that showed enhanced activity were tested again as triplicates. 
Values for NIH45-46 and NIH45-46G54W in Fig. S8A were obtained from three independent 
experiments. Similar IC50 values were obtained in two independent neutralization experiments using 
different dilution series.  
SUPPLEMENTARY DISCUSSION 
 
Comparison of Tyr74 in NIH45-46 and VRC01 
The conformation of heavy chain residue Tyr74, a FWR3 residue that was substituted during 
somatic hypermutation (16), differs in the NIH45-46 and VRC01 structures. In NIH45-46–
93TH057, the hydroxyl of Tyr74NIH45-46 hydrogen bonds with the carbonyl oxygen of Leu122gp120 in 
the bridging sheet (Fig. S4B). The Tyr74NIH45-46 sidechain adopts a similar orientation in the 
structure of unbound NIH45-46 despite a slight mainchain displacement (Fig. 1A). By contrast, in 
VRC01–93TH057, the Tyr74VRC01 sidechain is stabilized by Gly8VRC01 of a crystallographic 
neighbor; rather than hydrogen bonding with Leu122gp120, it approaches Gly124gp120 (part of a 
recombinant insert replacing V1-V2) (PDB code: 3NGB). As Tyr74VRC01 probably occupies space 
filled by the V1-V2 stem, the conformation of Tyr74 observed in NIH45-46–93TH057 is likely 
favored when interacting with spike trimers on a virion, implying that VRC01, like NIH45-46, 
targets the bridging sheet as part of its binding surface on gp120. However, the Leu122gp120 region 
of the bridging sheet was eliminated from the resurfaced RSC3 gp120 due to a truncation beginning 
at residue 121 (8) (Fig. S6). 
 
Comparison of NIH45-46 and VRC01 light chains 
Contacts between the antibody light chain and gp120 are mostly conserved between the NIH45-46–
93THO57 and VRC01–93THO57 structures with a notable exception: Ser28NIH45-46 LC in CDRL1 
replaces a solvent-exposed tyrosine (Tyr28VRC01 LC) that interacts with ordered N-linked 
carbohydrate attached to Asn27693TH057. By contrast, the Ser28NIH45-46 LC sidechain does not contact 
gp120 carbohydrates; instead it faces away from gp120, hydrogen bonding with Arg64NIH45-46 LC 
(FWR3) and creating a 2.7 Å displacement of the mainchain Cα atoms (Fig. S5A). The Ser28NIH45-46 
LC–Arg64NIH45-46 LC interaction is maintained in unbound NIH45-46 (Fig. S5B). The position 28 
substitution of serine for tyrosine largely accounts for the burial of more surface area in gp120’s 
interaction with the VRC01 versus NIH45-46 light chain (681 Å2 versus 395 Å2 total buried surface 
area; 314 Å2 versus 203 Å2 buried surface area on the light chain) (Table S4). The larger contact 
area for the VRC01 light chain may account for the ability of VRC01, but not NIH45-46, to 
neutralize the clade C CAP45.2.00.G3 strain, given that the NIH45-46 heavy chain paired with the 
VRC01 light chain neutralizes this strain, whereas the VRC01 heavy chain paired with the NIH45-
46 light chain does not (Table S10). However, the VRC01 light chain did not increase the potency of 
NIH45-46 against three other viral strains (Fig. S5C), suggesting that the Tyr28 interaction with 
gp120 carbohydrate is not obligatory. 
	  
Figure S1 
Fig. S1. Sequence alignment of NIH45-46 and VRC01 (residue are numbered as defined for 
VRC01 (8)). Circles mark NIH45-46 residues that contact gp120; unfilled circles indicate side 
chain contacts, red circles indicate main chain contacts, and blue circles indicate contacts with 
both the side and the main chain. Black arrows indicate the boundaries of complementarity 
determining regions (CDRs) as defined by IMGT (43), and residues within CDR loops as defined 
by the structure are marked with colors corresponding to the CDR colors in Fig. 1B. The 
locations of framework regions (FWRs) are indicated before, after, and between the CDRs. The 
definition of CDR2 in ref. (8) was the same as that defined by IMGT; however CDR2 was 
defined differently in refs. (25, 26) to include C-terminal residues within the C” β-strand and 
FWR3. 
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Figure S2 
 
Fig. S2. Comparisons of NIH45-46 and VRC01 from the gp120-bound structures. (A) NIH45-46 in 
shown in magenta (heavy chain) and pink (light chain) and VRC01 is cyan. The additional disulfide 
bond joining CDRH2 and CDRH3 is indicated by an asterisk and carbohydrate attached to Asn70 is 
shown as sticks. An arrow points to CDRH3, which includes a four-residue insertion in NIH45-46. 
(B) Conserved interactions in the gp120 contacts of NIH45-46 and VRC01. The antigen-binding 
regions of the NIH45-46 (magenta) and VRC01 (cyan) Fabs are shown complexed with 93TH053 
gp120 (gray with yellow CD4-binding loop and orange V5 loop). Contact residues that are 
conserved in both structures as sticks. 
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Figure S3 
Fig. S3. Hydrogen bonding within the gp120 CD4-binding loop. (A) A direct hydrogen bond 
(green dotted line) forms between main chain atoms of Gly54NIH45-46 (magenta) and Asp368gp120 
(gray), and two water molecules (red spheres) mediate a hydrogen bond network between 
NIH45-46 and the CD4-binding loop. (B) CD4 (yellow) forms two direct hydrogen bonds with 
the CD4-binding loop (31). (C) The carbonyl oxygen of Trp54VRC03 (cyan) forms a direct 
hydrogen bond with Asp368gp120 (PDB code: 3SE8) using a similar architecture as shown for 
NIH45-46 in panel A, demonstrating that a tryptophan can be accommodated at position 54 
without disrupting the hydrogen bond to Asp368gp120. 
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Figure S4 
	  
Fig. S4. Conformation of Tyr74NIH45-46 (see Supplementary Discussion). (A) Superimposition of 
NIH45-46 (magenta) and VRC01 (cyan) in the bound states shows different conformations of 
heavy chain residue Tyr74. The gp120 bridging sheet is green and asterisks indicate the 
recombinant Gly2 linker that replaces the V1-V2 loop. (B) Close-up showing the hydrogen bond 
between Tyr74NIH45-46 and the main chain carbonyl oxygen of Leu122gp120. 
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Figure S5 
Fig. S5. The NIH45-46 light chain  (see Supplementary Discussion). (A) Stereo view of the 
superimposition of NIH45-46 and VRC01 light chains (magenta and cyan, respectively). 
Tyr28VRC01 LC interacts with N-linked carbohydrate attached to Asn276gp120. By contrast, the side 
chain of the counterpart residue in NIH45-46, Ser28NIH45-46 LC, faces away from gp120 to 
hydrogen bond with Arg64NIH45-46 LC, which results in a 2.7 Å local displacement of the NIH45-
46 main chain relative to VRC01 (arrowheads point to Ca atoms of residue 28 in each structure). 
(B) Superimposition of NIH45-46light chain in the bound and unbound structures (magenta and 
green, respectively) showing hydrogen bonds between Ser28 and Arg64. (C) Comparisons of 
neutralization by wild-type versus light chain-swapped antibodies. Color-coded according to IC50 
values (µg/mL): red <0.1, orange 0.1-1, yellow 1-10, green 10-50, white > 50 (not neutralizing). 
????????
????????
?????
???????
?????
?
??
?????
?????
?????
?????
?????
??????
	  
Figure S6 
	  
Fig. S6. NIH45-46 contact surfaces that were mutated in RSC3. 93TH057 gp120 is shown using 
a ribbon diagram and color coded as in Fig. 1B. Residues at each contact interface are 
highlighted on the gp120 structure as a surface enclosing the contact residues. The surface area 
on the inner domain that is buried by contact with NIH45-46 is shown in pink with inner 
domain/bridging sheet residues that were mutated in RSC3 (8) in red.  
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Figure S7 
Fig. S7. Sensorgrams from SPR experiments comparing the binding of the indicated gp120 core 
proteins to NIH45-46 or NIH45-46G54W Fabs. The gp120 proteins were injected as a 
concentration series (500 nM to 31.2 nM; two-fold dilutions) over Fabs that were immobilized at 
a surface density of 1500 RU. (Similar results were obtained in independent experiments in 
which the IgGs were immobilized at 500 RU; data not shown). Best-fit binding curves (black 
lines) for a 1:1 binding model are superimposed on the raw data (orange). Corresponding 
residual plots are shown below each sensorgram. 	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Figure S8 
Fig. S8. Increased neutralization potency of NIH45-46G54W. (A) In vitro neutralization data for a 
panel of six viruses chosen to include NIH45-46–sensitive and resistant strains color-coded 
according to IC50 values (µg/ml): red <0.1, orange 0.1-1, yellow 1-10, green 10-50, white >50 
(not neutralizing). (B) Representative neutralization curves showing the activity of NIH45-
46G54W (red) and NIH45-46 (cyan). The experimental points are averaged values from three 
independent assays. Error bars indicate standard deviations. The IC50 value for NIH45-46 against 
strain DU172.17 was extrapolated from data that do not reach saturation in assays conducted 
with high concentrations to detect weak neutralizing activity. 
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Table S1 
Data collection and refinement statistics 
 
 5% of unique reflections were removed as a test set for the Rfree calculation. 
  Values in parentheses are for the highest resolution shell. 
 
 NIH45-46–93TH057 Fab NIH45-46 
Data collection   
Wavelength (Å) 0.953 0.953 
Space group P212121 P212121 
Cell dimensions   
a, b, c (Å) 69.1, 70.5, 217.7 49.4, 87.4, 166.4 
α, β, γ  (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 37.05-2.45 (2.51-2.45) 38.68-2.60 (2.67-2.60) 
Rmeas (%) 7.5 (66.9) 12.2 (105.6) 
Rmrgd-F (%) 11.6 (108.1) 13.1 (78.0) 
I / σI 10.8 (1.8) 12.83 (2.0) 
Completeness (%) 98.6 (98.7) 99.5 (99.9) 
Multiplicity 3.7 6.6 
Reflections 145342 150105 
Unique reflections 39062 22795 
   
Refinement   
Resolution (Å) 37.05-2.45 38.68-2.6 
No. reflections 38987 22692 
Rwork / Rfree 20.7 / 25.6 18.4 / 23.8 
No. atoms   
Protein 5989 3380 
Ligand/ion 148 37 
Water 67 125 
B-factors   
Protein 79.9 46.0 
Ligand/ion 106.4 80.9 
Water 62 42.0 
Ramachandran   
Favored (%) 96.12 96.49 
Allowed (%) 3.48 3.28 
Outlier (%) 0.40 0.23 
R.m.s. deviations   
Bond lengths (Å) 0.004 0.004 
Bond angles (°) 0.754 0.838 
Table S2 
Effects of the insertion in NIH45-46 on neutralization potency 
 
In vitro neutralization IC50 values (μg/mL) 
Virus Clade NIH45-46 WT 
NIH45-46 
Y99dA 
NIH45-46 
Δ99a-99d 
AC10.0.29 B 0.9 4.4 13 
TRO.11 B 1.9 >50 >50 
SC422661.8 B 0.05 0.08 1.4 
QH0692.42 B 0.7 2.1 3.7 
ZM214M.PL15.11 C 0.3 1.1 2.2 
CAP45.2.00.G3 C >50 >50 >50 
T257-31 CRF02 (A/G) 0.5 2.4 7.0 
 
 CDRH3 sequence 
NIH45-46 WT FCTRGKYCTARDYYNWDFEHWGRGAP 
NIH45-46 Y99dA FCTRGKYCTARDAYNWDFEHWGRGAP 
NIH45-46 Δ99a-99d FCTRGKYCT----YNWDFEHWGRGAP 
 
Color-coded according to IC50 values (μg/mL): red <0.1, orange 0.1-1, yellow 1-10, green 10-50, white > 
50 (not neutralizing). IC50 values for VRC01 tested against the same viral strains are shown in Fig. S5C. 
 
Table S3 
Comparison of in vitro neutralization data for viral strains with differences at 
residue 281 
 
Strain Sequence Residue 281gp120 
IC50* 
μg/mL 
Du156.12 QLLLNGSLAEEEIIIKSENLTDNIKTIIVQLNQSIGINCTRPNNNTRKSV I 0.01 
ZM197M.PB7 QLLLNGSLAEEEIIIRSENLTDNTKTIIVHLNESVEIECVRPNNNTRKSV T 0.14 
ZM214M.PL15 QLLLNGSLAEKEIMIRSENLTNNAKTIIVQLTEAVNITCMRPGNNTRRSV A 0.05 
ZM249M.PL1 QLLLNGSLAEKEIIIRSENITDNVKIIIVHLNESVEINCTRPNNNTRKSI V 0.02 
ZM53M.PB12 QLLLNGSTAEEDIIIRSENLTNNAKTIIVHLNESIEIECTRPGNNTRKSI A 0.65 
ZM109F.PB4 QLLLNGSLAEEEIVIRSENLTDNAKTIIVHLNKSVEIECIRPGNNTRKSI A 0.22 
ZM135M.PL10a QLLLNGSLSEEGIIIRSKNLTDNTKTIIVHLNESVAIVCTRPNNNTRKSI T 0.36 
 
* IC50 values for NIH45-46 are taken from ref. (16). 
Table S4 
Buried Surface Area (Å2) 
 FWR1 CDR1 FWR2 CDR2 FWR3 CDR3 Total Fab Interface on gp120 
 CDR2 + 
FWR356-65* 
NIH45-46 HC 0 35 51 181 551 326 1144 1097  576 
VRC01 HC 0 20 98 136 521 117 892 882  545 
NIH45-46 LC 35 8 0 0 0 159 203 192  0 
VRC01 LC 36 114 0 0 0 165 314 367  0 
*Box on the right with blue numbering: Residues that correspond to the CDR2 region as defined in ref. 
(25). 
 
 
Table S4. Buried surface areas were calculated using Areaimol in CCP4 (44). Color coding 
indicates the percent of the total buried surface area for each molecule. The insertion in CDRH3 
contributes to a higher total buried surface area between the NIH45-46 heavy chain and gp120 
compared with VRC01 (2241 Å2 versus 1774 Å2 total buried surface area; 1144 Å2 versus 892 
Å2 buried surface area on the heavy chain). The difference in heavy chain buried area is largely 
due to more extensive gp120 contacts of the CDRH3NIH45-46 loop: 326 Å2 of surface area of the 
NIH45-46 CDRH3 are buried by contacting gp120, compared with 117 Å2 for the VRC01 
CDRH3. The extra contacts with gp120 created by the CDRH3 insertion allow the NIH45-46 
footprint on gp120 to more closely resemble the CD4 footprint on gp120 than does the VRC01 
footprint (Fig. 3C). In particular, CD4 makes at least 1/3 of its contacts with the inner domain 
and bridging sheet of gp120, as opposed to only 13% of the total surface area contacted by 
VRC01 involving non-outer domain elements of gp120 (25). The contact area with the inner 
domain and bridging sheet is increased to 25% in the NIH45-46 footprint on gp120.  
 
<10% 
10-20% 
20-30% 
30-40% 
40-50% 
>50% 
 Inner 
domain & 
bridging 
sheet 
Loop D + 
NAG 
β-15/α-3 + 
NAG V5 β-24 
Outer 
domain exit 
loop 
Total 
gp120 
Interface on 
Fab or CD4 
NIH45-46 328 335 222 292 81 35 1290 1346 
VRC01 157 433 208 328 43 57 1225 1206 
CD4 400 136 263 155 14 97 973 1059 
 Table S5 
In vitro neutralization IC50 values (μg/mL) 
   NIH45-46 IC50 (μg/mL) 
Virus Clade Category WT G54W G54F G54Y 
6545.v4.c1 AC R >50 18.92 >50 >50 
6540.v4.c1 AC R >50 >50 >50 >50 
CAP45.2.00.G3 C R >50 32.25 >50 >50 
Du422.1 C R >50 >50 >50 >50 
CAP210.2.00.E8 C R >50 >50 >50 >50 
3817.v2.c59 CD R >50 >50 >50 >50 
89-F1_2_25 CD R >50 >50 >50 >50 
620345.c01 CRF01_AE R >50 >50 >50 >50 
T250-4 CRF02_AG R >50 1.33 >50 >50 
T278-50 CRF02_AG R >50 >50 >50 >50 
211-9 CRF02_AG R >50 16.41 >50 >50 
3016.v5.c45 D R >50 1.47 5.82 17.89 
Du172.17 C R >50 3.65 >50 >50 
3718.v3.c11 A P 19.61 0.01 0.32 0.30 
703357.C02 CRF01_AE P 19.17 3.43 7.91 5.60 
CNE20 BC P 7.83 0.04 0.53 0.33 
CNE21 BC P 6.01 0.03 0.12 0.07 
HIV-16845-2.22 C P 5.00 0.45 0.59 0.59 
C2101.c01 CRF01_AE P 4.24 0.04 0.11 0.09 
ZM247v1(Rev-) C P, T/F 2.94 0.32 0.28 0.42 
ZM233M.PB6 C P 2.50 0.02 0.22 0.16 
C1080.c03 CRF01_AE P 2.48 0.20 0.36 0.29 
THRO4156.18 B P 1.91 0.54 0.89 0.66 
3103.v3.c10 ACD P 1.770 0.200 0.370 0.300 
231966.c02 D P 1.640 0.020 0.060 0.060 
TRO.11 B P 1.610 0.040 0.110 0.080 
T251-18 CRF02_AG P 1.350 0.260 0.410 0.350 
Ce1176_A3 C S, T/F 0.930 0.160 0.240 0.210 
QH0692.42 B S 0.720 0.370 0.560 0.520 
T255-34 CRF02_AG S 0.710 <0.001 0.030 0.040 
ZM135M.PL10a C S 0.590 0.040 0.130 0.090 
AC10.0.29 B S 0.560 0.130 0.240 0.190 
T257-31 CRF02_AG S 0.490 0.130 0.170 0.180 
CNE58 BC S 0.430 0.020 0.040 0.040 
Ce0393_C3 C S, T/F 0.334 0.013 0.040 0.036 
R1166.c01 CRF01_AE S 0.310 0.130 0.400 0.240 
CNE30 BC S 0.309 0.052 0.100 0.099 
CNE17 BC S 0.261 0.036 0.075 0.073 
X2131_C1_B5 G S 0.230 0.050 0.100 0.100 
928-28 CRF02_AG S 0.230 0.060 0.110 0.120 
6535.3 B S 0.230 0.030 0.070 0.080 
 
Virus Clade Category WT G54W G54F G54Y 
ZM53M.PB12 C S 0.175 0.040 0.080 0.060 
ZM214M.PL15 C S 0.170 0.030 0.090 0.060 
Ce703010054_2A2 C S, T/F 0.159 0.027 0.020 0.022 
ZM197M.PB7 C S 0.150 0.040 0.090 0.070 
CAAN5342.A2 B S 0.150 0.070 0.100 0.100 
Q23.17 A S 0.140 0.010 0.030 0.020 
PVO.4 B S 0.120 0.050 0.070 0.060 
1054_07_TC4_1499 B S, T/F 0.113 0.040 0.076 0.064 
Ce2010_F5 C S, T/F 0.101 0.038 0.046 0.049 
ZM109F.PB4 C S 0.095 0.002 0.022 0.026 
1056_10_TA11_1826 B S, T/F 0.094 0.024 0.064 0.044 
0330.v4.c3 A S 0.090 0.030 0.040 0.030 
P1981_C5_3 G S 0.080 0.020 0.030 0.040 
Q461.e2 A S 0.076 0.009 0.030 0.023 
P0402_c2_11 G S 0.073 0.003 0.008 0.012 
SC422661.8 B S 0.060 0.020 0.040 0.040 
62357_14_D3_4589 B S, T/F 0.060 0.020 0.040 0.030 
WITO4160.33 B S 0.060 0.010 0.020 0.030 
Ce2060_G9 C S, T/F 0.058 0.005 0.022 0.021 
Ce0682_E4 C S, T/F 0.054 0.010 0.011 0.017 
231965.c01 D S 0.051 <0.001 0.022 0.025 
Q259.d2.17 A S 0.043 <0.001 0.009 0.009 
TRJO4551.58 B S 0.040 0.010 0.030 0.030 
6811.v7.c18 CD S 0.035 <0.001 0.017 0.011 
R2184.c04 CRF01_AE S 0.034 0.005 0.015 0.015 
6480.v4.c25 CD S 0.032 0.004 0.014 0.018 
X1254_c3 G S 0.032 0.002 0.011 0.013 
Q842.d12 A S 0.031 0.005 0.011 0.015 
C3347.c11 CRF01_AE S 0.029 <0.001 0.015 0.011 
1006_11_C3_1601 B S, T/F 0.027 <0.001 0.003 0.005 
3415.v1.c1 A S 0.022 <0.001 <0.001 <0.001 
X1193_c1 G S 0.021 <0.001 <0.001 0.006 
Du156.12 C S 0.020 <0.001 <0.001 0.007 
RHPA4259.7 B S 0.017 <0.001 0.005 0.007 
ZM249M.PL1 C S 0.017 0.002 0.004 0.003 
0815.v3.c3 ACD S 0.014 <0.001 <0.001 <0.001 
REJO4541.67 B S 0.014 0.002 0.007 0.007 
3301.v1.c24 AC S 0.009 <0.001 0.001 0.003 
Q769.d22 A S 0.009 <0.001 0.005 0.007 
CNE53 BC S 0.008 <0.001 0.005 0.006 
WEAU_d15_410_787 B S, T/F 0.005 <0.001 <0.001 0.002 
       
Geometric means   0.417 0.046 0.120 0.124 
       
Category R - Resistant S - Sensitive  
 P - Poorly sensitive T/F - Transmitted Founder  
    
IC50 values (μg/mL) 
color coding <0.01 0.01-0.1 0.1-1.0 1.0-10 10-50 >50 
Table S6 
In vitro neutralization IC80 values (μg/mL) 
   NIH45-46 IC80 (μg/mL) 
Virus Clade Category WT G54W G54F G54Y 
T250-4 CRF02_AG R >50 44.94 >50 >50 
703357.C02 CRF01_AE R >50 17.61 >50 30.58 
CAP45.2.00.G3 C R >50 >50 >50 >50 
CNE20 BC R >50 0.48 3.91 2.40 
CAP210.2.00.E8 C  R >50 >50 >50 >50 
T278-50 CRF02_AG R >50 >50 >50 >50 
211-9 CRF02_AG R >50 >50 >50 >50 
620345.c01 CRF01_AE R >50 >50 >50 >50 
3016.v5.c45 D R >50 15.37 36.97 >50 
3817.v2.c59 CD R >50 >50 >50 >50 
89-F1_2_25 CD R >50 >50 >50 >50 
6540.v4.c1 AC  R >50 >50 >50 >50 
6545.v4.c1 AC R >50 >50 >50 >50 
Du422.1 C P >50 >50 >50 >50 
3718.v3.c11 A P >50 0.04 4.620 3.85 
Du172.17 C P >50 42.85 >50 >50 
CNE21 BC P 38.07 0.16 0.66 0.29 
C2101.c01 CRF01_AE P 31.37 0.17 0.42 0.27 
ZM247v1(Rev-) C P, T/F 24.50 2.60 2.45 3.57 
HIV-16845-2.22 C P 22.61 2.10 2.75 2.75 
ZM233M.PB6 C P 14.18 0.11 0.99 0.78 
C1080.c03 CRF01_AE P 11.56 0.91 2.26 1.83 
231966.c02 D P 9.64 0.11 0.24 0.23 
THRO4156.18 B P 8.22 1.81 3.01 2.14 
TRO.11 B P 7.49 0.13 0.30 0.22 
3103.v3.c10 ACD P 6.15 0.56 1.28 0.81 
T251-18 CRF02_AG P 3.68 0.92 1.38 1.16 
T255-34 CRF02_AG S 3.442 0.099 0.198 0.174 
Ce1176_A3 C S, T/F 3.17 0.45 0.83 0.58 
ZM135M.PL10a C S 2.79 0.16 0.43 0.30 
CNE58 BC S 2.08 0.05 0.11 0.11 
AC10.0.29 B S 1.93 0.63 1.12 0.90 
QH0692.42 B S 1.71 1.12 1.65 1.50 
T257-31 CRF02_AG S 1.38 0.45 0.51 0.67 
R1166.c01 CRF01_AE S 1.21 0.51 1.32 0.84 
CNE30 BC S 1.067 0.196 0.348 0.263 
Ce0393_C3 C S, T/F 0.936 0.089 0.173 0.134 
X2131_C1_B5 G S 0.88 0.24 0.41 0.39 
CNE17 BC S 0.734 0.127 0.287 0.264 
928-28 CRF02_AG S 0.64 0.25 0.41 0.33 
 
 
 
Virus Clade Category WT G54W G54F G54Y 
ZM53M.PB12 C S 0.61 0.16 0.23 0.22 
ZM214M.PL15 C S 0.59 0.15 0.30 0.23 
ZM197M.PB7 C S 0.55 0.18 0.23 0.21 
6535.3 B S 0.54 0.13 0.27 0.24 
Ce703010054_2A2 C S, T/F 0.538 0.077 0.070 0.070 
Q23.17 A S 0.50 0.03 0.07 0.06 
1056_10_TA11_1826 B S, T/F 0.447 0.160 0.283 0.189 
ZM109F.PB4 C S 0.437 0.070 0.17 0.168 
PVO.4 B S 0.41 0.16 0.25 0.18 
1054_07_TC4_1499 B S, T/F 0.404 0.165 0.283 0.236 
CAAN5342.A2 B S 0.40 0.21 0.28 0.27 
Ce2010_F5 C S, T/F 0.357 0.187 0.186 0.235 
0330.v4.c3 A S 0.3 0.11 0.13 0.09 
Q461.e2 A S 0.291 0.091 0.135 0.103 
Ce2060_G9 C S, T/F 0.290 0.042 0.085 0.068 
WITO4160.33 B S 0.26 0.04 0.14 0.09 
P1981_C5_3 G S 0.24 0.07 0.11 0.09 
P0402_c2_11 G S 0.214 0.023 0.047 0.049 
1006_11_C3_1601 B S, T/F 0.196 0.008 0.024 0.021 
62357_14_D3_4589 B S, T/F 0.19 0.07 0.14 0.09 
Ce0682_E4 C S, T/F 0.155 0.039 0.056 0.065 
Q259.d2.17 A S 0.154 0.014 0.036 0.034 
SC422661.8 B  S 0.13 0.07 0.10 0.09 
TRJO4551.58 B S 0.13 0.05 0.08 0.07 
R2184.c04 CRF01_AE S 0.127 0.036 0.054 0.045 
231965.c01 D S 0.126 0.035 0.062 0.054 
6811.v7.c18 CD S 0.113 0.033 0.063 0.059 
X1254_c3 G S 0.107 0.018 0.043 0.041 
6480.v4.c25 CD S 0.100 0.021 0.046 0.051 
C3347.c11 CRF01_AE S 0.094 0.028 0.059 0.052 
3415.v1.c1 A S 0.086 0.023 0.029 0.037 
Q842.d12 A S 0.073 0.025 0.039 0.045 
X1193_c1 G S 0.064 0.009 0.026 0.024 
Du156.12 C S 0.054 0.005 0.019 0.026 
ZM249M.PL1 C S 0.053 0.007 0.016 0.011 
0815.v3.c3 ACD S 0.052 0.003 0.014 0.015 
RHPA4259.7 B S 0.047 0.007 0.020 0.020 
CNE53 BC S 0.039 0.005 0.024 0.027 
REJO4541.67 B S 0.035 0.013 0.028 0.020 
3301.v1.c24 AC S 0.033 0.004 0.011 0.014 
Q769.d22 A S 0.033 0.009 0.023 0.024 
WEAU_d15_410_787 B S, T/F 0.015 0.003 0.004 0.008 
       
Geometric means   1.231 0.225 0.437 0.393 
       
Category R - Resistant S - Sensitive  
 P - Poorly sensitive T/F - Transmitted Founder  
       
IC80 values (μg/mL) 
color coding <0.01 0.01-0.1 0.1-1.0 1.0-10 10-50 >50 
Table S7 
Sequence correlates of resistance to NIH45-46 
Strain gp120 residue variations that may affect NIH45-46 neutralization 
620345_c1 Ser456 (Arg) Asp459 (Gly) Lys279 (Asn/Asp) 
89_F1_2_25 Ser456 (Arg) Asn458 (Gly)  
6540_v4_c1 Ser456 (Arg) Tyr458 (Gly) Ser280 (Asn) 
6545_v4_c1 Ser456 (Arg) Tyr458 (Gly) Ser280 (Asn) 
Du422.1 Trp456 (Arg)   
T250_4 Pro459 (Gly)    
T278_50 Glu459 (Gly) Ala279 (Asn/Asp)  
Ce1172_H1 deletion of Gly459   
X2088_c9 Val459 (Gly)   
H086.8  Asp459 (Gly) Lys279 (Asn/Asp)  
 
Table S7. 10 of 17 NIH45-46–resistant strains (5 of 7 NIH45-46G54W–resistant strains, shown in 
bold) have amino acid variations at NIH45-46-contacting residues that have a fully conserved 
residue (shown in parenthesis) in all NIH45-46 sensitive strains. These mutations occur in the 
β23 strand immediately preceding V5 and in loop D. The positions of shaded sites have been 
shown to be important in resistance to VRC01 (33). 
For the remaining strains, resistance may relate to other features: 
Strain Possible NIH45-46 resistance correlate 
Du172.17 Lys462 (positive residue unusual at this position) 
3016.v5.c45 Tyr282 (Lys) (likely a steric issue – change in loop D conformation); neutralized 
by VRC01 
CAP45.2.00.G3 VRC01 light chain permits neutralization (Tyr28VRC01 LC-glycan at Asn276gp120) 
3817.v2.c59 Quaternary effect suggested in ref. (33) 
CAP210.2.00.E8 
246F C1G 
211-9 
 
Mechanism unclear 
 
 
The largest difference between sensitivity to NIH45-46 and sensitivity to VRC01 was in strain 
3016.v5.c45 (IC50s of >30 and 0.16 µg/mL, respectively). The most notable residue in 
3016.v5.c45 is Tyr282 in loop D. This large residue may alter the conformation of loop D, which 
is closely contacted by the four-residue insertion in the NIH45-46 CDRH3. The absence of the 
insertion may permit VRC01 to better accommodate an altered loop D. The next largest NIH45-
46/VRC01 difference, for strain C2101.c1 (12.78 vs. 0.36 µg/mL), may similarly relate to the 
unusual Lys99gp120 residue replacing the asparagine that favorably interacts with Arg99bNIH45-46 
in the NIH45-46–gp120 crystal structure. 	  
Table S8 
Effects of position 54 substitution in selected bNAbs 
 
In vitro neutralization IC50 values (μg/mL) 
Virus Clade 3BNC60 WT 
3BNC60 
T54W 
3BNC117
WT 
3BNC117
T54W 
3BNC55 
WT 
3BNC55 
T54W 
12A12 
WT 
12A12 
Y54W 
SC422661.8 B 0.1 0.1 0.07 0.07 0.3 0.6 0.2 0.2 
AC10.0.29 B 13 3.1 6.5 2.8 >50 >50 0.6 0.5 
TRO.11 B 0.07 0.06 0.6 0.6 7.6 >50 0.3 0.2 
Du172.17 C 0.05 0.04 0.04 0.9 2 >50 0.2 0.1 
CAP210.2.00.E8 C 4.7 5.0 11 2.8 >50 >50 >50 >50 
CAP45.2.00.G3 C 10 19 16 23 >50 >50 0.4 0.2 
 
Color-coded according to IC50 values (μg/mL): red <0.1, orange 0.1-1, yellow 1-10, green 10-50, white > 
50 (not neutralizing). 
 
Table S9 
Potencies of currently-available bNAbs 
 
 IC50 
 Isolate PGT-121 
PGT-
122 
PGT-
123 
PGT-
125 
PGT-
126 
PGT-
127 
PGT-
128 
PGT-
130 
PGT-
131 
PGT-
135 
PGT-
136 
PGT-
137 
PGT-
141 
PGT-
142 
PGT-
143 
PGT-
144 
PGT-
145 VRC01 
VRC-
PG04 PG9 
Geometric 
mean 0.53 1.03 0.66 1.85 1.05 2.92 0.39 3.07 7.27 9.53 30.39 23.53 3.15 2.40 3.14 13.62 0.91 0.45 0.57 1.27 
Arithmetic 
mean 16.63 19.39 18.29 25.81 21.75 26.19 15.31 25.39 31.06 34.91 44.02 41.22 24.62 23.30 24.62 33.76 12.83 4.41 7.92 15.89 
In
clu
de
 >
50
 (μ
g/
m
L)
 
Median 0.31 2.02 0.35 34.97 1.08 42.83 0.10 22.98 50.00 50.00 50.00 50.00 16.01 9.46 13.76 50.00 0.86 0.34 0.30 0.62 
                      
Geometric 
mean 0.07 0.13 0.08 0.09 0.08 0.17 0.06 0.24 0.41 0.32 2.25 1.68 0.33 0.24 0.34 1.58 0.30 0.32 0.30 0.36 
Arithmetic 
mean 2.17 3.21 2.44 3.34 2.82 2.39 1.56 3.09 2.80 3.88 12.74 10.51 3.80 2.99 4.32 6.87 2.59 1.04 1.99 4.33 
Median 0.03 0.05 0.03 0.04 0.04 0.08 0.02 0.16 0.52 0.17 7.81 3.46 0.35 0.21 0.31 2.06 0.29 0.32 0.20 0.23 
Ex
clu
de
 >
50
 (μ
g/
m
L)
 
% viruses 
<50 (μg/mL) 70% 65% 67% 52% 60% 50% 72% 52% 40% 33% 16% 22% 55% 57% 56% 38% 78% 92% 88% 75% 
 
 
 
Table S9. Potencies of currently-available bNAbs. (A) Comparison of mean and median IC50 
(µg/mL) values for PGT antibodies and VRC01. A direct comparison between NIH45-46 and the 
PGT antibodies is not available. However VRC01 (which was shown in a direct comparison to 
be less potent than NIH45-46 (16)) was directly compared to the PGT antibodies using the same 
virus panel (18) and thus can serve as a reference for comparing NIH45-46 to the PGT 
antibodies. Mean IC50 values were calculated using data taken from ref. (18). Geometric and 
arithmetic means were calculated to include data for all viral strains (listed as Include >50, in 
which case, values reported as IC50 >50 µg/mL were entered as 50 µg/mL in the calculation) and 
to exclude viral strains in which the IC50 was >50 µg/mL (listed as Exclude >50, in which case 
the percent of viral strains with IC50s < 50 µg/mL is also reported). Mean IC50s are compared 
with the median IC50s as reported in ref. (18). The table is color-coded according to IC50 values 
(µg/mL): red <0.1, orange 0.1-1, yellow 1-10, green 10-50, white >50 (not neutralizing) or the 
percent of viral strains neutralized: red >90, orange 80-90, yellow 70-80, green 50-70, white <50. 
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